These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16004665)

  • 1. Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes.
    Home P
    Curr Med Res Opin; 2005 Jul; 21(7):989-98. PubMed ID: 16004665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What does postprandial hyperglycaemia mean?
    Heine RJ; Balkau B; Ceriello A; Del Prato S; Horton ES; Taskinen MR
    Diabet Med; 2004 Mar; 21(3):208-13. PubMed ID: 15008828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-prandial hyperglycaemia and vascular disease.
    Hanefeld M
    Int J Clin Pract Suppl; 2000 Sep; (112):13-8. PubMed ID: 11064946
    [No Abstract]   [Full Text] [Related]  

  • 4. Postprandial hyperglycaemia: noxious effects on the vessel wall.
    Hanefeld M
    Int J Clin Pract Suppl; 2002 Jul; (129):45-50. PubMed ID: 12166606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature.
    Nalysnyk L; Hernandez-Medina M; Krishnarajah G
    Diabetes Obes Metab; 2010 Apr; 12(4):288-98. PubMed ID: 20380649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes.
    Gallagher A; Home PD
    Diabetes Res Clin Pract; 2005 Mar; 67(3):196-203. PubMed ID: 15713351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postprandial and basal hyperglycaemia in type 2 diabetes: Contributions to overall glucose exposure and diabetic complications.
    Monnier L; Colette C
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S9-6S15. PubMed ID: 26774019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rise and fall of HbA(1c) as a risk marker for diabetes complications.
    Kilpatrick ES
    Diabetologia; 2012 Aug; 55(8):2089-91. PubMed ID: 22711013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postprandial glucose and vascular disease.
    Haller H
    Diabet Med; 1997 Aug; 14 Suppl 3():S50-6. PubMed ID: 9272614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence.
    Bonora E; Muggeo M
    Diabetologia; 2001 Dec; 44(12):2107-14. PubMed ID: 11793012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimates of the relative and absolute diurnal contributions of fasting and post-prandial plasma glucose over a range of hyperglycaemia in type 2 diabetes.
    Peter R; Dunseath G; Luzio SD; Owens DR
    Diabetes Metab; 2013 Sep; 39(4):337-42. PubMed ID: 23993831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Postprandial hyperglycemia. Postprandial blood glucose fluctuations, cardiovascular disease and late diabetic complications].
    Madsbad S; Brock B; Schmitz O
    Ugeskr Laeger; 2003 Aug; 165(33):3149-53. PubMed ID: 12968409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperglycaemia and its relation to cardiovascular morbidity and mortality: has it been resolved?
    Yosefy C
    Acta Diabetol; 2003 Dec; 40 Suppl 2():S380-8. PubMed ID: 14704873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention.
    Unwin N; Shaw J; Zimmet P; Alberti KG
    Diabet Med; 2002 Sep; 19(9):708-23. PubMed ID: 12207806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose control in diabetes: which target level to aim for?
    Laakso M; Cederberg H
    J Intern Med; 2012 Jul; 272(1):1-12. PubMed ID: 22321169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept.
    Monnier L; Colette C; Owens DR
    Diabetes Metab Res Rev; 2009 Jul; 25(5):393-402. PubMed ID: 19437415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes.
    Caballero AE; Arora S; Saouaf R; Lim SC; Smakowski P; Park JY; King GL; LoGerfo FW; Horton ES; Veves A
    Diabetes; 1999 Sep; 48(9):1856-62. PubMed ID: 10480619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycaemic control is essential for effective cardiovascular risk reduction across the type 2 diabetes continuum.
    Karasik A
    Ann Med; 2005; 37(4):250-8. PubMed ID: 16019723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In search of normoglycaemia in diabetes: controlling postprandial glucose.
    Del Prato S
    Int J Obes Relat Metab Disord; 2002 Sep; 26 Suppl 3():S9-17. PubMed ID: 12174318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.